- Oops!Something went wrong.Please try again later.
BOSTON, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Block & Leviton is investigating BeyondSpring, Inc. (NASDAQ: BYSI) for potential securities law violations. Investors who have lost money in their BeyondSpring investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/bysi.
What is this all about?
Before the market opened on December 1, 2021, BeyondSpring announced receipt of a Complete Response Letter (CRL) from the U.S. Food & Drug Administration (FDA) rejecting the company’s new drug application (NDA) for a treatment regimen to treat chemotherapy-induced neutropenia containing its drug Plinabulin.
Shares of BeyondSpring stock fell more than 50% in pre-market and intraday trading on December 1, 2021.
Who is eligible?
Anyone who purchased BeyondSpring, Inc. stock and has lost money may be eligible, whether or not they have sold their investment. Investors should contact Block & Leviton to learn more.
What is Block & Leviton doing?
Block & Leviton is investigating whether the Company committed securities law violations and may file an action to attempt to recover losses on behalf of investors who have lost money.
What should you do next?
Why should you contact Block & Leviton?
Many law firms have issued releases about this matter; most of those firms do not actually litigate securities class actions. Block & Leviton is a law firm that actually litigates cases. We are dedicated to obtaining significant recoveries on behalf of defrauded investors through active litigation in the federal courts across the country. Many of the nation's top institutional investors hire us to represent their interests. You can learn more about us at our website, www.blockleviton.com, or call (617) 398-5600 or email email@example.com with any questions.
This notice may constitute attorney advertising.
BLOCK & LEVITON LLP
260 Franklin St., Suite 1860
Boston, MA 02110
Phone: (617) 398-5600
SOURCE: Block & Leviton LLP